IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a “Buy” Recommendation and $3.50 Price Target July 18, 2024 Read More »
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile July 9, 2024 Read More »
IGC Pharma’s TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer’s Disease June 25, 2024 Read More »
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta-9-tetrahydrocannabinol June 10, 2024 Read More »
IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1 May 28, 2024 Read More »
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two April 16, 2024 Read More »
